Healthcare provider profile · identity verified

Charles E Meadows, MD

Internal Medicine · HUNTINGTON, WV · NPI 1750346318

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	256	77
Losartan Potassium	Losartan Potassium	256	72
Atorvastatin Calcium	Atorvastatin Calcium	243	79
Gabapentin	Gabapentin	219	45
Levothyroxine Sodium	Levothyroxine Sodium	194	55
Omeprazole	Omeprazole	194	48
Lisinopril	Lisinopril	192	50
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	173	45
Metformin Hcl	Metformin Hcl	169	45
Simvastatin	Simvastatin	168	47
Carvedilol	Carvedilol	151	42
Alprazolam	Alprazolam	135	30
Sertraline Hcl	Sertraline Hcl	123	30
Pravastatin Sodium	Pravastatin Sodium	121	27
Potassium Chloride	Potassium Chloride	120	36
Tamsulosin Hcl	Tamsulosin Hcl	119	33
Metoprolol Succinate	Metoprolol Succinate	111	33
Furosemide	Furosemide	107	32
Albuterol Sulfate Hfa	Albuterol Sulfate	105	32
Eliquis	Apixaban	104	22
Metoprolol Tartrate	Metoprolol Tartrate	103	30
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	99	15
Allopurinol	Allopurinol	93	26
Fluticasone Propionate	Fluticasone Propionate	86	30
Trazodone Hcl	Trazodone Hcl	85	23
Pantoprazole Sodium	Pantoprazole Sodium	76	28
Rosuvastatin Calcium	Rosuvastatin Calcium	73	20
Tramadol Hcl	Tramadol Hcl	72	11
Meloxicam	Meloxicam	70	18
Hydrochlorothiazide	Hydrochlorothiazide	62	19
Mirtazapine	Mirtazapine	59	13
Montelukast Sodium	Montelukast Sodium	59	22
Duloxetine Hcl	Duloxetine Hcl	56	16
Esomeprazole Magnesium	Esomeprazole Magnesium	49	12
Famotidine	Famotidine	49	15
Ozempic	Semaglutide	49	suppressed
Spironolactone	Spironolactone	48	14
Escitalopram Oxalate	Escitalopram Oxalate	41	16
Fluoxetine Hcl	Fluoxetine Hcl	40	11
Lorazepam	Lorazepam	39	suppressed
Ondansetron Hcl	Ondansetron Hcl	39	11
Symbicort	Budesonide/Formoterol Fumarate	39	suppressed
Buspirone Hcl	Buspirone Hcl	36	13
Clopidogrel	Clopidogrel Bisulfate	36	14
Dicyclomine Hcl	Dicyclomine Hcl	36	suppressed
Ezetimibe	Ezetimibe	36	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	36	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	34	suppressed
Jardiance	Empagliflozin	34	suppressed
Methylprednisolone	Methylprednisolone	34	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Clonazepam	Clonazepam	30	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Valsartan	Valsartan	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	suppressed
Glimepiride	Glimepiride	26	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Celecoxib	Celecoxib	24	suppressed
Oxycodone Hcl	Oxycodone Hcl	24	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Multaq	Dronedarone Hcl	22	suppressed
Torsemide	Torsemide	22	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	21	suppressed
Finasteride	Finasteride	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Atenolol	Atenolol	19	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Azithromycin	Azithromycin	16	14
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Oxycontin	Oxycodone Hcl	16	suppressed
Spiriva Handihaler	Tiotropium Bromide	16	suppressed
Diazepam	Diazepam	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Promethazine Hcl	Promethazine Hcl	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Dantrolene Sodium	Dantrolene Sodium	13	suppressed
Linzess	Linaclotide	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Admelog Solostar	Insulin Lispro	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Estradiol	Estradiol	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Nicotrol Ns	Nicotine	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	11	suppressed
Felodipine Er	Felodipine	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Novolin N Flexpen	Insulin Nph Human Isophane	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error